ERBB2 and gastric cancer: On the basis of ORIENT-16, the National Medical Products Administration (NMPA) of China granted approval for a combined therapy of sintilimab in combination with certain types of chemotherapy (XELOX) for the initial treatment of patients with advanced or metastatic GC or GEJC (non-HER2-positive tumors) [5].